708262-58-2

Upstream product

• 598-21-0 2-Bromoacetyl bromide 
• 95-55-6 2-amino-phenol 
• 22118-09-8 2-bromoacetyl chloride 

Downstream Products

• 905509-75-3 2-[{5-(4-nitrophenyl)-1,3,4-oxadiazole-2-yl}sulphanyl]-N-(2-hydroxyphenyl)acetamide 
• 5466-88-6 3,4-dihydro-3-oxo-2H-1,4-benzoxazine 
• 26673-71-2 ethyl 2-(3-oxo-2,3-dihydro-4H-benzo[b][1,4]oxazin-4-yl)acetate 

Relevant academic research and scientific papers

INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE

The present disclosure discloses compounds capable of modulating the activity of α-amino-β-carboxymuconic acid semialdehyde decarboxylase (ACMSD), which are useful for the prevention and/or the treatment of diseases and disorders associated with defects in NAD+ biosynthesis, e.g., metabolic disorders, neurodegenerative diseases, chronic inflammatory diseases, kidney diseases, and diseases associated with ageing. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament.

Synthesis, characterization and biological evaluation of m-phenetidine derivatives

Summary: The synthesis of compounds bearing sulfamoyl group and amide linkage is pharmacologically important due to their splendid biological activities. In the presented research work N-(3-ethoxyphenyl)-4-methylbenzenesulfonamide (3) was synthesized by the coupling of m-phenetidine (1) with 4-methylbenzenesulfonyl chloride (2) in basic aqueous media. Compound 3 on reaction with 2-bromo-N-aryl/aralkyl substituted acetamides, 5a-d, synthesized the products, 6a-d. The bromination of compound 3 yielded N-(2,4-dibromo-5-ethoxyphenyl)-4-methylbenzenesulfonamide (7) which on further treatment with different electrophiles, 8a-d yielded compound 9a-d. Enzyme inhibition activities of all the synthesized compounds were evaluated against acetylcholinesterase, butyrylcholinesterase, lipoxygenase, urease, chymotrypsin and tyrosinase enzymes; and found to be the most prominent inhibitor of tyrosinase enzyme.

N-substituted derivatives of 5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl-2- sulfanyl acetamide as valuable bioactive compounds

In the described research work, a new series of N-substituted derivatives of 5-(4- chlorophenyl)-1,3,4-Oxadiazol-2-yl-2-sulfanyl acetamide has been synthesized. The synthesis was carried out by converting 4-chlorobenzoic acid (1) into ethyl 4-chlorobenzoate (2), 4- chlorobenzohydrazide (3) and then 5-(4-chlorophenyl)-1,3,4-Oxadiazol-2-thiol (4) respectively. The target molecules 6a-o were synthesized by reacting compound 4 with different N-alkyl/aryl substituted 2-bromoacetamide (5a-o) in equimolar ratios of using DMF and sodium hydride (NaH). The structure of all the synthesized compounds was confirmed by spectral data like EI-MS, IR and 1H-NMR. The compounds were also analysed for antimicrobial & hemolytic activity and most of them were found active against the selected microbial species at variable extent relative to reference standards. But 6f and 6o were the active against the selected panel of microbes and former was most potent one. This series revealed less toxicity and may consider for further biological screening and application trial except 6g and 6j, exhibiting high cytotoxicity.

Structure-activity relationships in the binding of chemically derivatized CD4 to gp120 from human immunodeficiency virus

The first step in HIV infection is the binding of the envelope glycoprotein gp120 to the host cell receptor CD4. An interfacial "Phe43 cavity" in gp120, adjacent to residue Phe43 of gp120-bound CD4, has been suggested as a potential target for therapeutic intervention. We designed a CD4 mutant (D1D2F43C) for site-specific coupling of compounds for screening against the cavity. Altogether, 81 cysteine-reactive compounds were designed, synthesized, and tested. Eight derivatives exceeded the affinity of native D1D2 for gp120. Structure-activity relationships (SAR) for derivatized CD4 binding to gp120 revealed significant plasticity of the Phe43 cavity and a narrow entrance. The primary contacts for compound recognition inside the cavity were found to be van der Waals interactions, whereas hydrophilic interactions were detected in the entrance. This first SAR on ligand binding to an interior cavity of gp120 may provide a starting point for structure-based assembly of small molecules targeting gp120-CD4 interaction.

Synthesis and vasorelaxant activity of new 1,4-benzoxazine derivatives potassium channel openers

As part of a search for new potassium channel openers, the synthesis and vasorelaxant activity of new 1,4-benzoxazine derivatives derived from transformation of the benzopyran skeleton of cromakalim were described. Several new 1,4-benzoxazine derivatives were provided with significant vasorelaxant activity with an overall pharmacological behavior similar to CRK (1f, 1i, 2d, 2e, 2f and 2i).

Synthesis, biological activity and conformational study of 1,4- benzoxazine derivatives as potassium channel modulators

With the aim of discovering new molecules with K+-channel activating properties, we have synthesized derivatives of cromakalim (CRK), an important molecule which shows specific affinity towards K+ channels, by replacing the benzopyrane ring of this reference compound with a 1,4-benzoxazine moiety. A different number of substituents showing a good discrimination between hydrophobic and electronic properties have been inserted at the 6-position of the 1,4-benzoxazine ring. We describe here the synthesis and discuss the solid state conformation of these new molecules. When tested on rat aorta ring precontracted with phenylephrine, two compounds (2c and 2d) showed a concentration-dependent relaxation similar to that measured for cromakalim but less potent than this reference drug.